Compare AstraZeneca plc (AZN) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Google Inc — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while Google Inc trades at $354.7 (market cap $4.37T). The key difference: Google Inc is far larger — about 17.3× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | GOOG | |
|---|---|---|
Market Cap | $253.13B | $4.37T |
Sector | Health | Technology |
52-Week High | $209.48 | $399.06 |
52-Week Low | $137.44 | $183.10 |
Enterprise Value | $279.37B | $4.34T |
Dividend Yield | 1.92% | 0.25% |
Volume | — | 1,511,127 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Alphabet (GOOG) trades at $350.67, down 1.23% amid bearish technical signals, though fundamentals remain robust with strong earnings beats and 32.8% net margin. Revenue grew to $402.84B in 2025, while analyst consensus is overwhelmingly bullish with an 86.84% buy rating and $457.50 price target. Recent news highlights AI advancements and regulatory scrutiny.
Outlook is positive given earnings momentum and AI leadership, but risks include regulatory probes and high valuation multiples. The stock offers growth potential with disciplined risk management advised amid technical weakness and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
